Vigil Neuroscience Inc

07/24/2024 | Press release | Distributed by Public on 07/24/2024 05:32

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.